AC Immune Ltd Cash Flow Conversion Efficiency
AC Immune Ltd cash flow conversion efficiency. Based on the latest financial reports, AC Immune Ltd (ACIU) has a cash flow conversion efficiency ratio of -0.366x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.45 Million) by net assets ($44.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AC Immune Ltd (2013–2025)
Cash flow conversion efficiency of AC Immune Ltd from 2013 to 2025. This chart illustrates how AC Immune Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ACIU stock price and chart for real-time trading data and today's change.
AC Immune Ltd Cash Flow Conversion Ratio Explained
AC Immune Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AC Immune Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AC Immune Ltd ranked by their cash flow conversion efficiency. Also see ACIU market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thejo Engineering Limited
NSE:THEJO
|
0.074x |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
-0.058x |
|
Genesyslogic
TWO:6104
|
0.039x |
|
WildBrain Ltd
TO:WILD
|
0.095x |
|
Froch Enterprise Co Ltd
TW:2030
|
-0.035x |
|
Mandala Multifinance Tbk
JK:MFIN
|
-0.027x |
|
Z.M.H Hammerman Ltd
TA:ZMH
|
-0.103x |
|
Columbus Circle Capital Corp III Class A Ordinary Shares
NASDAQ:CCCT
|
N/A |
Annual Cash Flow Conversion Efficiency for AC Immune Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of AC Immune Ltd from 2013 to 2025. Review AC Immune Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.93 Million | $-66.15 Million | -1.472x | -351.01% |
| 2024-12-31 | $112.27 Million | $65.84 Million | 0.586x | +255.96% |
| 2023-12-31 | $160.64 Million | $-60.41 Million | -0.376x | +13.62% |
| 2022-12-31 | $168.99 Million | $-73.57 Million | -0.435x | -53.74% |
| 2021-12-31 | $231.98 Million | $-65.69 Million | -0.283x | -2.52% |
| 2020-12-31 | $215.48 Million | $-59.52 Million | -0.276x | -236.27% |
| 2019-12-31 | $272.44 Million | $55.22 Million | 0.203x | +181.68% |
| 2018-12-31 | $177.62 Million | $-44.08 Million | -0.248x | -31.23% |
| 2017-12-31 | $116.84 Million | $-22.09 Million | -0.189x | -376.86% |
| 2016-12-31 | $142.38 Million | $-5.65 Million | -0.040x | -106.39% |
| 2015-12-31 | $71.04 Million | $44.08 Million | 0.621x | +182.63% |
| 2014-12-31 | $23.47 Million | $-17.62 Million | -0.751x | +81.57% |
| 2013-12-31 | $4.86 Million | $-19.80 Million | -4.075x | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more